RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability
13.9.2023 16:57:00 EEST | Business Wire | Press release
RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, was part of a collaboration that recently shared new preclinical data at the IASLC 2023 World Conference on Lung Cancer in Singapore. The data, presented by Dr. Dean Fennell, represented a partnership between RS Oncology and other lead research institutions, including the University of Leicester and the Cunniff Laboratory at the University of Vermont Cancer Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912702236/en/
“Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options. Our findings here might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study. Dr. Fennell and Dr. Cunniff shown at lunch during AACR conference 2023. (Photo courtesy of George Naumov)
Mesotheliomas can transform from a less aggressive epithelioid malignancy to a more aggressive sarcomatoid form. Using biphasic mesotheliomas as a model containing both epithelioid and sarcomatoid features, investigators at the University of Leicester, led by Dr. Fennell, conducted a geospatial analysis of patient tissues to explore the molecular signatures associated with the histological regions.
Using sophisticated spatial analysis tools coupled with machine learning approaches, the group found that the more aggressive sarcomatoid regions had distinct molecular signatures driving pro-tumor pathways, drug resistance, and increased metastatic potential. These findings were validated across an independent cohort of 150 mesothelioma patient tissues. Notably, tumor regions containing sarcomatoid tissue showed features of increased resistance to oxidative stress – a critical tumor cell adaptation for survival.
In collaboration with Dr. Brian Cunniff’s laboratory, the team then evaluated molecular signatures of human biphasic mesothelioma tumor cells following treatment with the irreversible PRX3 inhibitor RSO-021, which is currently being evaluated in a Phase 1/2 clinical trial in patients with malignant pleural effusion caused by advanced/metastatic solid tumors (NCT05278975). RSO-021 treatment reversed the gene signatures associated with epithelial-to-sarcomatoid transition, including downregulation of hypoxia, glycolysis, and epithelial-to-mesenchymal transition (EMT)-associated genes. These results suggest that this transition, thought to be unidirectional in nature, may be PRX3-dependent, druggable, and now reversible.
“Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options. Our findings might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study. “The ability to treat such tumors with RSO-021 and revert them to epithelioid malignancies could delay or even prevent emergence of the most aggressive features associated with mesothelioma. Further, RSO-021 could potentially sensitize them to other treatments.”
Presentation Details
Abstract Number: MA17.11
Session:
MA17 - Current Standards and Future Directions in Mesothelioma
Title: Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT Axis that is Reversible via PRX3 Inhibition
Date: Tuesday, September 12, 10:45 AM UTC +8
About RS Oncology
RS Oncology (RSO) is a clinical stage biotechnology company based in Cambridge, Massachusetts with a mission to eradicate mesothelioma and other diseases worldwide through novel science and an innovative business model.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912702236/en/
Contact information
Jarrett Duncan, CEO
j.duncan@rsoncology.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women23.9.2026 15:30:00 EEST | Press release
The Estée Lauder Companies today announced a new five-year commitment to the Breast Cancer Research Foundation to establish the Global Research Initiative on Breast Cancer in Younger Women. This first-of-its-kind research coalition will address the alarming global rise in breast cancer diagnoses among younger women, building on more than three decades of partnership between The Estée Lauder Companies and the Breast Cancer Research Foundation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923337773/en/ The $15 millioncommitment from The Estée Lauder Companies Charitable Foundation is designed to confront an urgent and significantly underfunded need. Diagnoses among women under age 45 increased by 11 percent from 2012 to 2022,1 while an estimated only 0.6 percent of breast cancer research funding since 2020 has focused on younger women. Breast cancer in younger women is more likely to be diagnosed at a later stage and to b
Enginzyme Raises SEK 75 Million to Advance Its Commercial Biomanufacturing Strategy23.9.2026 15:07:00 EEST | Press release
Enginzyme AB has closed a new equity round raising SEK 75 million. The round marks a key milestone in the company's shift from R&D to a commercially driven strategy. "With our growth strategy established, closing this new investment round was a priority for enginzyme," said Aymeric de Gantes, enginzyme's CEO. "We are also very excited to welcome new shareholders with complementary expertise, who will all contribute to our mission to deliver biomanufacturing solutions for the personal care, food, and pharmaceutical industries. Our technology enables lower cost in use for higher-quality ingredients, obtained through more sustainable manufacturing processes." Lotus One Investment Pte. Ltd. and Valquest Partners Europe are joining the company as new shareholders and members of the Board of Directors. Sofinnova Partners, Stiftelsen Industrifonden, Navigare Ventures AB and Almi Invest GreenTech were key participants, combined with several other new and existing shareholders. On Thursday, Sep
SLB Awarded Major Contract by OQEP for Integrated Facility Expansion in Oman23.9.2026 15:04:00 EEST | Press release
SLB (NYSE: SLB) has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922635677/en/ SLB has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. The expansion will increase the facility’s gross fluids handling capacity to 548,000 barrels per day. The project is scheduled for completion within 19 months. The award marks the next phase of development for the Bisa
Datavault AI Announces Rights Offering to Shareholders23.9.2026 15:03:00 EEST | Press release
Datavault AI Inc. (Nasdaq: DVLT) (“Datavault AI” or the “Company”), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing and tokenization technologies, today announced that its board of directors (the “Board”) has approved a rights offering to holders of its common stock (“Common Stock”) and certain other Datavault AI securities. Moody Capital Solutions, Inc. (“Moody Capital”) will act as dealer manager for the rights offering. The Rights Offering to include investors in a process usually reserved exclusively for banks Under the rights offering, the Company will distribute, at no charge, transferable subscription rights to holders of record of Common Stock and certain other Company securities with a contractual right to participate in the distribution. The Company has set a record date of October 9, 2026 for such offering (the “Record Date”). Such holders will receive one subscription right for a Common Unit for each share of Common Stock owned
Copeland Completes Acquisition of Dickson, Advancing Cold Chain Intelligence for Healthcare and Life Sciences23.9.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced it has completed the acquisition of Dickson, a Chicago-based provider of environmental monitoring and compliance technology solutions for highly regulated life sciences and healthcare environments. Increasing regulatory demands across the pharmaceutical and life sciences cold chain require continuous visibility from production through final delivery. Together, Dickson’s cloud-native monitoring platform and Copeland’s controls, monitoring and enterprise software solutions will enable a more connected, intelligent and compliant cold chain. “We are pleased to welcome our new colleagues from Dickson into Copeland,” said Ross B. Shuster, CEO of Copeland. “The acquisition of Dickson further strengthens our ability to serve customers across every stage of the healthcare and life sciences cold chain, from pharmaceutical manufacturing through distribution and patient care.” Enabling a Smarter, More Con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom